{"analyses":[{"ciLowerLimit":"0.976","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"1.090","groupDescription":"Arm B Vs Arm A","groupIds":["OG000","OG001"],"nonInferiorityComment":"The primary hypothesis tests was based on one-sided test at significance level of alpha = 0.05 to demonstrate the non-inferiority of the amivantamab SC-CF relative to amivantamab IV.","nonInferiorityType":"NON_INFERIORITY","paramType":"Geometric mean ratio","paramValue":"1.032"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"30.7","value":"135861"},{"groupId":"OG001","spread":"24.0","value":"131704"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"140"},{"groupId":"OG001","value":"132"}],"units":"Participants"}],"description":"AUC (Day 1-15) defined as area under the concentration time curve from Cycle 2 Day 1 to Day 15 were reported.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants were administered lazertinib 240 milligrams (mg) tablet orally once daily from Cycle 1 Day 1 until Cycle 15, with each cycle consisting of 28 days. Participants then received amivantamab subcutaneous injection with at dose 1600 mg (if body weight \\[BW\\] is less than \\[\\<\\] 80 kilograms \\[kg\\]) or 2240 mg (if BW is greater than or equal to \\[\\>=\\] 80 kg) co-formulated (SC-CF) with recombinant human hyaluronidase PH20 (rHuPH20) 160 milligrams per milliliter (mg/mL) through manual injection on Cycle 1 Days 1, 8, 15, and 22, and on Days 1 and 15 of each subsequent cycle, starting from Cycle 2. After the completion of primary analysis, participants who benefited from the study treatment continued their treatment within the study upon transitioning into the LTE phase.","id":"OG000","title":"Arm A: Lazertinib With Amivantamab SC-CF"},{"description":"Participants were administered lazertinib 240 mg orally once daily from Cycle 1 Day 1 until Cycle 15, with each cycle consisting of 28 days. Participants then received amivantamab intravenous infusion at dose 1050 mg (if BW\\< 80 kg) or 1400 mg (if BW \\>=80 kg) on Cycle 1 Days 1-2 (split dose), 8, 15, 22, and on Days 1 and 15 of each subsequent cycle, starting from Cycle 2. After the completion of primary analysis, participants who benefited from the study treatment continued their treatment within the study upon transitioning into the LTE phase.","id":"OG001","title":"Arm B: Lazertinib With Amivantamab Intravenous (IV) Infusion"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The PK primary endpoint evaluable set included all randomized participants who had received all doses up to Cycle 2 Day 1, without dose modifications and provided all necessary PK samples to derive primary PK endpoint Cycle 2 AUC(D1-D15). Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Cycle 2: Arm A: pre-dose, 24, 48, 72, 96, 168, and 360 hours (hrs) post-dose on Day 1; Arm B: pre-infusion, end of infusion (EOI)+10 minutes, EOI+2, EOI+6, EOI+24, EOI+48, EOI+72, EOI+168, and EOI+360 hrs post dose on Day 1","title":"Area Under the Concentration (AUC) Time Curve of Amivantamab From Day 1 to Day 15 (AUC [Day 1-15]) of Cycle 2","type":"PRIMARY","unitOfMeasure":"micrograms*hour per milliliters"}